Loading clinical trials...
Loading clinical trials...
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Nivolumab
Docetaxel
Locations
119
United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Local Institution - 0009
Duarte, California, United States
Local Institution - 0042
San Diego, California, United States
San Francisco Oncology Associates
San Francisco, California, United States
Yale University
New Haven, Connecticut, United States
Local Institution - 0034
Tampa, Florida, United States
Start Date
November 2, 2012
Primary Completion Date
February 5, 2015
Completion Date
December 17, 2021
Last Updated
February 8, 2023
NCT04439890
NCT03792074
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions